Integrated Multiprofessional Health Residency Program-Neonatal Intensive Care Unit, Pharmacy Department, Health Sciences Centre, Universidade Federal do Rio Grande do Norte, Natal, RN, Brazil.
School Maternity Januário Cicco, Health Sciences Centre, Universidade Federal do Rio Grande Norte, Natal, RN, Brazil.
PLoS One. 2018 Sep 25;13(9):e0204427. doi: 10.1371/journal.pone.0204427. eCollection 2018.
To evaluate the use of off-label and unlicensed medicines in a neonatal intensive care unit (NICU) of a teaching maternity hospital specialized in high risk pregnancy.
A prospective cohort study was conducted between August 2015 and July 2016. All newborns admitted to the NICU who had at least one medication prescribed and a hospital stay longer than 24 hours were included. The classification of off-label and unlicensed drugs for the neonatal population was done according to the information of Food and Drug Administration.
A total of 17421 medication items were analyzed in 3935 prescriptions of 220 newborns. The proportion of newborns exposed to off-label drugs was 96.4%, and to unlicensed medicines was 66.8%. About one-half (49.3%) of the medication items were off-label and 24.6% were unlicensed. The main reason for off-label and unlicensed classification was, respectively, frequency of administration and the administration of adaptations of pharmaceutical forms.
Although there are actions to encourage the development of pharmacological studies with neonates, this study observed a high rate of prescription and exposure of newborns to off-label and unlicensed drugs in NICUs and pointed out areas of neonatal therapy that require scientific investment.
评估一家专门治疗高危妊娠的教学妇产医院新生儿重症监护病房(NICU)中使用未经批准和标签外使用的药物的情况。
这是一项 2015 年 8 月至 2016 年 7 月期间进行的前瞻性队列研究。所有在 NICU 住院且至少有一次药物处方且住院时间超过 24 小时的新生儿均被纳入研究。根据美国食品和药物管理局的信息,对新生儿人群的标签外和未批准药物进行分类。
共分析了 220 名新生儿的 3935 张处方中的 17421 个药物项目。暴露于标签外药物的新生儿比例为 96.4%,暴露于未批准药物的比例为 66.8%。约一半(49.3%)的药物项目是标签外的,24.6%是未批准的。标签外和未批准分类的主要原因分别是给药频率和药物剂型的适应性给药。
尽管已经采取了一些措施来鼓励开展针对新生儿的药理学研究,但本研究观察到 NICU 中新生儿处方和暴露于标签外和未批准药物的比率较高,这表明新生儿治疗领域需要进行科学投资。